CITIC Construction Investment Securities' research report pointed out that YUYUE MEDICAL's annual report performance met expectations, with Q1 revenue slightly exceeding expectations and profit in line with expectations. Looking ahead to the whole year, with the recovery of domestic consumer demand and the continuous increase in the company's market share, the company's domestic business is expected to maintain a steady growth trend; as the company continues to accelerate its overseas channel layout and brand building, its overseas business is expected to maintain rapid growth. In the short term, the company's core businesses such as respiratory therapy and blood glucose management have strong market competitiveness. In the medium to long term, with the improvement of public health awareness and the continuous iteration and enrichment of the company's new products, the company's leading position in the domestic home medical device platform is expected to remain solid, and its global market share is expected to increase. Maintain a "Buy" rating